Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349.HK)
HKD 2.57
(5.76%)
HKD 2.57
(5.76%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 650.14 Million CNY | -21.06% |
| 2022 | 823.55 Million CNY | -5.44% |
| 2021 | 870.9 Million CNY | 43.57% |
| 2020 | 606.61 Million CNY | -13.99% |
| 2019 | 705.31 Million CNY | 32.86% |
| 2018 | 530.87 Million CNY | 38.63% |
| 2017 | 382.93 Million CNY | -11.33% |
| 2016 | 431.87 Million CNY | 10.2% |
| 2015 | 391.89 Million CNY | 25.33% |
| 2014 | 312.68 Million CNY | 11.93% |
| 2013 | 279.35 Million CNY | 90.13% |
| 2012 | 146.92 Million CNY | 109.14% |
| 2011 | 70.25 Million CNY | 5.23% |
| 2010 | 66.75 Million CNY | 31.49% |
| 2009 | 50.77 Million CNY | 20.84% |
| 2008 | 42.01 Million CNY | 0.05% |
| 2007 | 41.99 Million CNY | 32.63% |
| 2006 | 31.66 Million CNY | -20.41% |
| 2005 | 39.78 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 141.8 Million CNY | 29.15% |
| 2024 Q1 | 132.34 Million CNY | 19.73% |
| 2023 Q1 | 145.64 Million CNY | -31.08% |
| 2023 Q2 | 247.24 Million CNY | 69.76% |
| 2023 FY | 650.14 Million CNY | -21.06% |
| 2023 Q3 | 146.72 Million CNY | -40.66% |
| 2023 Q4 | 110.53 Million CNY | -24.67% |
| 2022 Q2 | 176.91 Million CNY | 31.05% |
| 2022 Q4 | 211.32 Million CNY | -37.72% |
| 2022 FY | 823.55 Million CNY | -5.44% |
| 2022 Q3 | 339.32 Million CNY | 91.8% |
| 2022 Q1 | 134.99 Million CNY | -58.25% |
| 2021 FY | 870.9 Million CNY | 43.57% |
| 2021 Q1 | 122.83 Million CNY | -46.5% |
| 2021 Q2 | 194.9 Million CNY | 58.67% |
| 2021 Q3 | 227.11 Million CNY | 16.53% |
| 2021 Q4 | 323.35 Million CNY | 42.38% |
| 2020 FY | 606.61 Million CNY | -13.99% |
| 2020 Q3 | 198.07 Million CNY | 56.2% |
| 2020 Q2 | 126.8 Million CNY | 148.86% |
| 2020 Q1 | 50.95 Million CNY | -79.98% |
| 2020 Q4 | 229.6 Million CNY | 15.91% |
| 2019 Q2 | 193.87 Million CNY | 152.94% |
| 2019 Q1 | 76.64 Million CNY | -59.83% |
| 2019 Q4 | 254.52 Million CNY | 39.85% |
| 2019 FY | 705.31 Million CNY | 32.86% |
| 2019 Q3 | 181.99 Million CNY | -6.13% |
| 2018 Q4 | 190.79 Million CNY | 0.0% |
| 2018 FY | 530.87 Million CNY | 38.63% |
| 2018 Q2 | 101.92 Million CNY | 0.0% |
| 2018 Q3 | 190.79 Million CNY | 87.2% |
| 2018 Q1 | 101.92 Million CNY | 17.03% |
| 2017 Q3 | 87.08 Million CNY | -10.32% |
| 2017 Q4 | 87.08 Million CNY | 0.0% |
| 2017 Q2 | 97.11 Million CNY | 0.0% |
| 2017 Q1 | 97.11 Million CNY | -22.5% |
| 2017 FY | 382.93 Million CNY | -11.33% |
| 2016 Q3 | 125.3 Million CNY | 44.35% |
| 2016 Q2 | 86.8 Million CNY | 0.0% |
| 2016 Q1 | 86.8 Million CNY | -22.86% |
| 2016 FY | 431.87 Million CNY | 10.2% |
| 2016 Q4 | 125.3 Million CNY | 0.0% |
| 2015 FY | 391.89 Million CNY | 25.33% |
| 2015 Q4 | 112.53 Million CNY | 0.0% |
| 2015 Q2 | 77.1 Million CNY | 0.0% |
| 2015 Q3 | 112.53 Million CNY | 45.95% |
| 2015 Q1 | 77.1 Million CNY | -24.66% |
| 2014 Q3 | 102.34 Million CNY | 104.09% |
| 2014 Q4 | 102.34 Million CNY | 0.0% |
| 2014 FY | 312.68 Million CNY | 11.93% |
| 2014 Q1 | 50.14 Million CNY | -50.41% |
| 2014 Q2 | 50.14 Million CNY | 0.0% |
| 2013 Q2 | 76.38 Million CNY | 123.19% |
| 2013 Q4 | 101.11 Million CNY | 49.51% |
| 2013 FY | 279.35 Million CNY | 90.13% |
| 2013 Q1 | 34.22 Million CNY | -46.06% |
| 2013 Q3 | 67.63 Million CNY | -11.46% |
| 2012 FY | 146.92 Million CNY | 109.14% |
| 2012 Q4 | 63.44 Million CNY | 149.78% |
| 2012 Q3 | 25.4 Million CNY | -45.07% |
| 2012 Q2 | 46.24 Million CNY | 290.82% |
| 2012 Q1 | 11.83 Million CNY | -31.11% |
| 2011 Q3 | 23.63 Million CNY | 22.27% |
| 2011 FY | 70.25 Million CNY | 5.23% |
| 2011 Q1 | 8.22 Million CNY | -65.03% |
| 2011 Q2 | 19.32 Million CNY | 134.89% |
| 2011 Q4 | 17.17 Million CNY | -27.33% |
| 2010 FY | 66.75 Million CNY | 31.49% |
| 2010 Q4 | 23.53 Million CNY | 83.04% |
| 2010 Q3 | 12.85 Million CNY | -25.8% |
| 2010 Q2 | 17.32 Million CNY | 32.8% |
| 2010 Q1 | 13.04 Million CNY | 0.0% |
| 2009 Q2 | 10.18 Million CNY | 0.0% |
| 2009 FY | 50.77 Million CNY | 20.84% |
| 2008 FY | 42.01 Million CNY | 0.05% |
| 2007 FY | 41.99 Million CNY | 32.63% |
| 2006 FY | 31.66 Million CNY | -20.41% |
| 2005 FY | 39.78 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 24.42 Million HKD | -2561.896% |
| Grand Pharmaceutical Group Limited | 3.86 Billion HKD | 83.16% |
| Extrawell Pharmaceutical Holdings Limited | 35.52 Million HKD | -1729.992% |
| Wai Yuen Tong Medicine Holdings Limited | 353.93 Million HKD | -83.691% |
| Qianhai Health Holdings Limited | 17.1 Million HKD | -3701.552% |
| Lee's Pharmaceutical Holdings Limited | 590.99 Million HKD | -10.008% |
| Essex Bio-Technology Limited | 1.22 Billion HKD | 47.098% |
| Tongfang Kontafarma Holdings Limited | 503.46 Million HKD | -29.134% |
| PuraPharm Corporation Limited | 216.62 Million HKD | -200.117% |
| SSY Group Limited | 1.98 Billion HKD | 67.177% |
| JBM (Healthcare) Limited | 163.87 Million HKD | -296.728% |
| Jacobson Pharma Corporation Limited | 287.34 Million HKD | -126.255% |
| China Resources Pharmaceutical Group Limited | 29.35 Billion HKD | 97.785% |